Renin, a marker for left ventricular hypertrophy, in primary aldosteronism: a cohort study

in European Journal of Endocrinology
View More View Less
  • 1 Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU München, Munich, Germany
  • | 2 Klinik und Poliklinik für Radiologie, Klinikum der Universität München, LMU München, Munich, Germany
  • | 3 Klinik für Viszeral- und Endokrine Chirurgie, Klinikum der Universität München, LMU München, Munich, Germany

Correspondence should be addressed to C Adolf Email Christian.Adolf@med.uni-muenchen.de
Restricted access

Context

Primary aldosteronism (PA) causes left ventricular hypertrophy (LVH) via hemodynamic factors and directly by aldosterone effects. Specific treatment by mineralocorticoid receptor antagonists (MRA) or adrenalectomy (ADX) has been reported to improve LVH. However, the cardiovascular benefit could depend on plasma renin concentration (PRC) in patients on MRA.

Patients and objective

We analyzed data from 184 patients from the Munich center of the German Conn’s Registry, who underwent echocardiography at the time of diagnosis and 1 year after treatment. To assess the effect of PRC on cardiac recovery, we stratified patients on MRA according to suppression (n = 46) or non-suppression of PRC (n = 59) at follow-up and compared them to PA patients after ADX (n = 79).

Results

At baseline, patients treated by ADX or MRA had comparable left ventricular mass index (LVMI, 61.7 vs 58.9 g/m2.7, P  = 0.591). Likewise, patients on MRA had similar LVMI at baseline, when stratified into treatment groups with suppressed and unsuppressed PRC during follow-up (60.0 vs 58.1 g/m2.7, P  = 0.576). In all three groups, we observed a significant reduction in LVMI following treatment (P  < 0.001). However, patients with suppressed PRC had no decrease in pro-BNP levels, and the reduction of LVMI was less intense than in patients with unsuppressed PRC (4.1 vs 8.2 g/m2.7, P  = 0.033) or after ADX (9.3 g/m2.7, P  = 0.019). Similarly, in multivariate analysis, higher PRC was correlated with the regression of LVH.

Conclusion

PA patients with suppressed PRC on MRA show impaired regression of LVH. Therefore, dosing of MRA according to PRC could improve their cardiovascular benefit.

 

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 815 815 123
Full Text Views 75 75 4
PDF Downloads 108 108 6
  • 1

    Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, Gabetti L, Mengozzi G, Williams TA & Rabbia F et al.Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. Journal of the American College of Cardiology 2017 69 18111820. (https://doi.org/10.1016/j.jacc.2017.01.052)

    • Search Google Scholar
    • Export Citation
  • 2

    Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet, Diabetes and Endocrinology 2018 6 4150. (https://doi.org/10.1016/S2213-8587(1730319-4)

    • Search Google Scholar
    • Export Citation
  • 3

    Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Journal of the American College of Cardiology 2005 45 12431248. (https://doi.org/10.1016/j.jacc.2005.01.015)

    • Search Google Scholar
    • Export Citation
  • 4

    Catena C, Colussi G, Marzano L, Sechi LA. Aldosterone and the heart: from basic research to clinical evidence. Hormone and Metabolic Research 2012 44 181187. (https://doi.org/10.1055/s-0031-1291318)

    • Search Google Scholar
    • Export Citation
  • 5

    Tsai CH, Pan CT, Chang YY, Chen ZW, Wu VC, Hung CS, Lin YH. Left ventricular remodeling and dysfunction in primary aldosteronism. Journal of Human Hypertension 2021 35 131147. (https://doi.org/10.1038/s41371-020-00426-y)

    • Search Google Scholar
    • Export Citation
  • 6

    Marney AM, Brown NJ. Aldosterone and end-organ damage. Clinical Science 2007 113 267278. (https://doi.org/10.1042/CS20070123)

  • 7

    Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996 27 10391045. (https://doi.org/10.1161/01.hyp.27.5.1039)

    • Search Google Scholar
    • Export Citation
  • 8

    Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995 92 175182. (https://doi.org/10.1161/01.cir.92.2.175)

    • Search Google Scholar
    • Export Citation
  • 9

    Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young Jr WF. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2016 101 18891916. (https://doi.org/10.1210/jc.2015-4061)

    • Search Google Scholar
    • Export Citation
  • 10

    Mulatero P, Sechi LA, Williams TA, Lenders JWM, Reincke M, Satoh F, Januszewicz A, Naruse M, Doumas M & Veglio F et al.Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the working group on endocrine hypertension of the European Society of Hypertension. Journal of Hypertension 2020 38 19291936. (https://doi.org/10.1097/HJH.0000000000002520)

    • Search Google Scholar
    • Export Citation
  • 11

    Grytaas MA, Sellevag K, Thordarson HB, Husebye ES, Lovas K, Larsen TH. Cardiac magnetic resonance imaging of myocardial mass and fibrosis in primary aldosteronism. Endocrine Connections 2018 7 413424. (https://doi.org/10.1530/EC-18-0039)

    • Search Google Scholar
    • Export Citation
  • 12

    Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, Giorgi D, Scognamiglio R, Mariani M, Pessina AC. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002 40 2327. (https://doi.org/10.1161/01.hyp.0000023182.68420.eb)

    • Search Google Scholar
    • Export Citation
  • 13

    Indra T, Holaj R, Strauch B, Rosa J, Petrak O, Somloova Z, Widimsky Jr J. Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism. Journal of the Renin-Angiotensin-Aldosterone System 2015 16 11091117. (https://doi.org/10.1177/1470320314549220)

    • Search Google Scholar
    • Export Citation
  • 14

    Rossi GP, Cesari M, Cuspidi C, Maiolino G, Cicala MV, Bisogni V, Mantero F, Pessina AC. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 2013 62 6269. (https://doi.org/10.1161/HYPERTENSIONAHA.113.01316)

    • Search Google Scholar
    • Export Citation
  • 15

    Marzano L, Colussi G, Sechi LA, Catena C. Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies. American Journal of Hypertension 2015 28 312318. (https://doi.org/10.1093/ajh/hpu154)

    • Search Google Scholar
    • Export Citation
  • 16

    Adolf C, Kohler A, Franke A, Lang K, Riester A, Low A, Heinrich DA, Bidlingmaier M, Treitl M & Ladurner R et al.Cortisol excess in patients with primary aldosteronism impacts left ventricular hypertrophy. Journal of Clinical Endocrinology and Metabolism 2018 103 45434552. (https://doi.org/10.1210/jc.2018-00617)

    • Search Google Scholar
    • Export Citation
  • 17

    Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, Sechi LA. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007 50 911918. (https://doi.org/10.1161/HYPERTENSIONAHA.107.095448)

    • Search Google Scholar
    • Export Citation
  • 18

    Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes and Endocrinology 2018 6 5159. (https://doi.org/10.1016/S2213-8587(1730367-4)

    • Search Google Scholar
    • Export Citation
  • 19

    Shenasa M, Shenasa H. Hypertension, left ventricular hypertrophy, and sudden cardiac death. International Journal of Cardiology 2017 237 6063. (https://doi.org/10.1016/j.ijcard.2017.03.002)

    • Search Google Scholar
    • Export Citation
  • 20

    Adolf C, Heinrich DA, Holler F, Lechner B, Nirschl N, Sturm L, Gorge V, Riester A, Williams TA & Treitl M et al.Patients with primary aldosteronism respond to unilateral adrenalectomy with long-term reduction in salt intake. Journal of Clinical Endocrinology and Metabolism 2020 105 e484e493. (https://doi.org/10.1210/clinem/dgz051)

    • Search Google Scholar
    • Export Citation
  • 21

    Betz MJ, Degenhart C, Fischer E, Pallauf A, Brand V, Linsenmaier U, Beuschlein F, Bidlingmaier M, Reincke M. Adrenal vein sampling using rapid cortisol assays in primary aldosteronism is useful in centers with low success rates. European Journal of Endocrinology 2011 165 301306. (https://doi.org/10.1530/EJE-11-0287)

    • Search Google Scholar
    • Export Citation
  • 22

    Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young Jr WF, Montori VM & Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2008 93 32663281. (https://doi.org/10.1210/jc.2008-0104)

    • Search Google Scholar
    • Export Citation
  • 23

    Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J & Shanewise JS et al.Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. Journal of the American Society of Echocardiography 2005 18 14401463. (https://doi.org/10.1016/j.echo.2005.10.005)

    • Search Google Scholar
    • Export Citation
  • 24

    Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J & Shanewise J et al.Recommendations for chamber quantification. European Journal of Echocardiography 2006 7 79108. (https://doi.org/10.1016/j.euje.2005.12.014)

    • Search Google Scholar
    • Export Citation
  • 25

    de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. Journal of the American College of Cardiology 1995 25 10561062. (https://doi.org/10.1016/0735-1097(9400540-7)

    • Search Google Scholar
    • Export Citation
  • 26

    Kunzel HE, Apostolopoulou K, Pallauf A, Gerum S, Merkle K, Schulz S, Fischer E, Brand V, Bidlingmaier M & Endres S et al.Quality of life in patients with primary aldosteronism: gender differences in untreated and long-term treated patients and associations with treatment and aldosterone. Journal of Psychiatric Research 2012 46 16501654. (https://doi.org/10.1016/j.jpsychires.2012.08.025)

    • Search Google Scholar
    • Export Citation
  • 27

    Remde H, Hanslik G, Rayes N, Quinkler M. Glucose metabolism in primary aldosteronism. Hormone and Metabolic Research 2015 47 987993. (https://doi.org/10.1055/s-0035-1565208)

    • Search Google Scholar
    • Export Citation
  • 28

    Lechner B, Lechner K, Heinrich DA, Adolf C, Holler F, Schneider H, Beuschlein F, Reincke M. THERAPY OF ENDOCRINE DISEASE: Medical treatment of primary aldosteronism. European Journal of Endocrinology 2019 181 R147R153. (https://doi.org/10.1530/EJE-19-0215)

    • Search Google Scholar
    • Export Citation
  • 29

    Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiology 2018 3 768774. (https://doi.org/10.1001/jamacardio.2018.2003)

    • Search Google Scholar
    • Export Citation
  • 30

    Puar TH, Loh LM, Loh WJ, Lim DST, Zhang M, Tan PT, Lee L, Swee DS, Khoo J & Tay D et al.Outcomes in unilateral primary aldosteronism after surgical or medical therapy. Clinical Endocrinology 2021 94 158167. (https://doi.org/10.1111/cen.14351)

    • Search Google Scholar
    • Export Citation
  • 31

    Tezuka Y, Turcu AF. Mineralocorticoid receptor antagonists decrease the rates of positive screening for primary aldosteronism. Endocrine Practice 2020 26 14161424. (https://doi.org/10.4158/EP-2020-0277)

    • Search Google Scholar
    • Export Citation
  • 32

    Ferreira JP, Verdonschot J, Wang P, Pizard A, Collier T, Ahmed FZ, Brunner-La-Rocca HP, Clark AL, Cosmi F & Cuthbert J et al.Proteomic and mechanistic analysis of spironolactone in patients at risk for HF. JACC: Heart Failure 2021 9 268277. (https://doi.org/10.1016/j.jchf.2020.11.010)

    • Search Google Scholar
    • Export Citation
  • 33

    Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003 108 18311838. (https://doi.org/10.1161/01.CIR.0000091405.00772.6E)

    • Search Google Scholar
    • Export Citation
  • 34

    Funder JW Primary aldosteronism and cardiovascular risk, before and after treatment. Lancet Diabetes and Endocrinology 2018 6 57. (https://doi.org/10.1016/S2213-8587(1730368-6)

    • Search Google Scholar
    • Export Citation
  • 35

    Baudrand R, Guarda FJ, Torrey J, Williams G, Vaidya A. Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 2016 101 39893996. (https://doi.org/10.1210/jc.2016-1963)

    • Search Google Scholar
    • Export Citation
  • 36

    Diet, nutrition and the prevention of chronic diseases. World Health Organization Technical Report Series 2003 916 iviii, 1149.

  • 37

    Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G & Dominiczak A et al.2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal 2018 39 30213104. (https://doi.org/10.1093/eurheartj/ehy339)

    • Search Google Scholar
    • Export Citation
  • 38

    Sadee W, Dagcioglu M, Schroder R. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. Journal of Pharmacology and Experimental Therapeutics 1973 185 686695.

    • Search Google Scholar
    • Export Citation
  • 39

    Hartmann MF, Reincke M, Wudy SA, Bernhardt R. The human adrenal gland as a drug metabolizer: first in-vivo evidence for the conversion of steroidal drugs. Journal of Steroid Biochemistry and Molecular Biology 2019 194 105438. (https://doi.org/10.1016/j.jsbmb.2019.105438)

    • Search Google Scholar
    • Export Citation
  • 40

    Pouleur AC, le Polain de Waroux JB, Pasquet A, Gerber BL, Gerard O, Allain P, Vanoverschelde JL. Assessment of left ventricular mass and volumes by three-dimensional echocardiography in patients with or without wall motion abnormalities: comparison against cine magnetic resonance imaging. Heart 2008 94 10501057. (https://doi.org/10.1136/hrt.2007.123711)

    • Search Google Scholar
    • Export Citation
  • 41

    Einstadter D, Bolen SD, Misak JE, Bar-Shain DS, Cebul RD. Association of repeated measurements with blood pressure control in primary care. JAMA Internal Medicine 2018 178 858860. (https://doi.org/10.1001/jamainternmed.2018.0315)

    • Search Google Scholar
    • Export Citation
  • 42

    Beckerhoff R, Nussberger J, Vetter W, Siegenthaler W. Problems connected with plasma renin activity measurements by angiotensin I radioimmunoassay. Hormone and Metabolic Research 1975 7 342347. (https://doi.org/10.1055/s-0028-1093727)

    • Search Google Scholar
    • Export Citation
  • 43

    Morganti A, Pelizzola D, Mantero F, Gazzano G, Opocher G, Piffanelli A. Immunoradiometric versus enzymatic renin assay: results of the Italian multicenter comparative study: Italian multicenter study for standardization of renin measurement. Journal of Hypertension 1995 13 1926.

    • Search Google Scholar
    • Export Citation